Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Status:
Recruiting
Trial end date:
2022-01-22
Target enrollment:
Participant gender:
Summary
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab
to participants with advanced or metastatic sarcomas that will not cause serious side
effects.